Specific pharmacological inhibition of LRH-1 resulted in reduced activation- and LRH-1-induced FasL expression and cytotoxicity in T cells, and inhibited FasL-dependent liver damage in the context of experimental hepatitis in vivo. This evidence concerns the gene FASLG and Hepatitis.